オプションチェーンは、Agilon Healthの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Agilon Healthの市場センチメントを評価します。.

Agilon Health (NYSE:AGL) 株価情報, オプションチェーン

Agilon Health

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

Agilon Health Inc

T2 Metals Corp

Adventure Gold - United States Dollar

AUSTRAL GOLD LTD ORD by Austral Gold Ltd.

Austral Gold Ltd

ANGELALIGN TECH INC by Angelalign Technologies Inc.

Angelalign Technology Inc

AGL Energy Ltd

AGILITY REAL EST NEW by Agility Real Estate Inc.

Agility Real Estate Inc

ANGEL TELECOM CORP by Angel Telecom Corp.

AgileThought Inc

ATLANTIS GLORY INC by Atlantis Glory Inc.

Atlantis Glory Inc

Raymond James analyst James Rollyson maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Strong Buy and lowers the price target from $41 to $37.

News

Price Target

Analyst Ratings

Raymond James Maintains Strong Buy on Halliburton, Lowers Price Target to $37

4 analysts have shared their evaluations of Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $29.75, a high estimate of $33.00, and a low estimate of $23.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.03%. 
<img src="https://www.benzinga.com/files/images/story/2024/1731088809_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Immunome among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Immunome. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Immunome compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Immunome's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Immunome's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IMNM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Immunome analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Immunome Better</h2>
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
<h3>Financial Insights: Immunome</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Immunome's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -44.55% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1528.0%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Immunome's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -13.39%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Immunome's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -11.73%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Immunome's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IMNM

Analyst Expectations For Immunome's Future

Barclays analyst Seth Sigman maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Overweight and lowers the price target from $15 to $13.

ARHS

Barclays Maintains Overweight on Arhaus, Lowers Price Target to $13

Shares of Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) tumbled in early trading on Friday, after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41826457/block-shares-sink-after-mixed-q3-results-eps-beat-revenues-miss">mixed third-quarter results</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<ul>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60216a57879cba00010f246b/david-williams">analyst Mayank Tandon</a> maintained a Buy rating, while raising the price target from $80 to $90.</li>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f777c10bd99100018a435e/tien-tsin-huang">analyst Tien-tsin Huang</a> reiterated an Overweight rating and price target of $90.</li>
<li>Stephens <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/624d5d9d72b50e0001afdf24/charles-nabhan">analyst Charles Nabhan</a> reaffirmed an Overweight rating and price target of $90.</li>
<li>Oppenheimer <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d3cdb8b85e930001808a5c/rayna-kumar">analyst Rayna Kumar</a> maintained a Perform rating on the stock.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Needham: Block's GPV (gross payment volume) came in at $62.5 billion, up 4% year-on-year, but missed consensus of $64.33 billion consensus, while gross profit of $2.25 billion, beat consensus of $2.24 billion, Tandon said. Although GPV weakness weighed on transaction revenues, "healthy margins and operating leverage fueled better profitability," he added.
The company raised its full-year guidance due to better third-quarter results, but its fourth-quarter outlook was "lighter than expected on both gross profit and EBITDA," the analyst stated. "We believe the softer 4Q guide reflects persistent pressure on Seller GPV growth and higher than expected investments in sales and marketing," he further wrote.
JPMorgan: Block's quarterly results were "solid," but the negative surprise was a reduction in the fourth-quarter guidance, Huang said. Management's preliminary 2025 outlook of at least 15% growth in gross profit "assumes acceleration through the year inclusive of improving Square GPV growth, a critical watch item for investors given underperformance vs. peers and the market," he added.
"With this guide, the execution bar has been set higher for next year," the analyst wrote. While gross profit growth decelerated through the year in 2024, Block will need to "accelerate from a +14% exit rate in FY24, putting its various product, GTM and organizational initiatives to the test for it to achieve similar upside as it has this year," he further wrote.
Stephens: Block's third-quarter beat was driven by expense control, Nabhan said. Cash App's gross profit grew by 21% year-on-year, while Square's gross profit rose 16%, with GPV decelerating to 7.6% year-on-year, from 8% in the second quarter, he added.
The company raised its full-year adjusted operating income by $120 million, which reflected the third-quarter beat, the analyst stated. "Given GP growth/adj op margin of 18%, the outlook equates to 36% on a rule of 40 basis, vs. 35% prior," he further wrote.
Oppenheimer: Block's adjusted EBITDA grew 69% to $807 million and beat consensus of $707 million, but total GPV rose by only 2%, missing Street&#8217;s 5% estimate, Kumar said. Cash App's GPV contracted by 40%, versus Street&#8217;s estimate of a 9% decline, while Square's GPV growth of 8% came in-line with expectations, he added.
Investor concerns around the company's slowing top-line growth "were evident in results," the analyst stated. Block seems well-positioned for continued market share gains, but upside potential is limited by its "relatively high exposure to discretionary consumer spend, small businesses and the non-affluent demographic," he further wrote.
Price Action: Shares of Block had declined by 5.52% to $71.08 at the time of publication on Friday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41833692/jack-dorsey-reaffirms-blocks-bitcoin-centric-vision-to-boost-digital-wallet-mining-businesses-companys-btc-stash-grows-by-15m-in-q3">Jack Dorsey Reaffirms Block&#8217;s Bitcoin-Centric Vision To Boost Digital Wallet, Mining Businesses— Company&#8217;s BTC Stash Grows By $15M In Q3</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Reiteration

Movers

Trading Ideas

Block Reports Mixed Q3, Analysts Consider Preliminary 2025 Outlook As Aggressive

Barclays analyst Saket Kalia maintains Alarm.com Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRM#NASDAQ">ALRM</a>) with a Equal-Weight and raises the price target from $60 to $67.

ALRM

Barclays Maintains Equal-Weight on Alarm.com Holdings, Raises Price Target to $67

BofA Securities analyst Salvator Tiano upgraded International Flavors &amp; Fragrances, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) to Buy from Neutral, <a href="https://www.benzinga.com/quote/IFF/analyst-ratings">lowering the price forecast to $107 from $109</a>.
Per the analyst, International Flavors has exceeded earnings expectations in all three quarters this year under its new CEO, while working to revitalize its R&amp;D organization and product pipeline.
The company reported third quarter net sales of $2.93 billion, up 4% year-over-year, driven by strong performance in Health &amp; Biosciences, <a href="https://www.benzinga.com/pressreleases/24/11/b41758164/iff-reports-third-quarter-2024-results">Scent, Nourish, and Pharma Solutions</a>. Volume grew high-single digits and improved across all businesses.
The analyst projects end-market demand to improve in 2025-26, following a period of pressure. Innovation is also regaining momentum after years of SKU reductions, although the analyst cautions not to overstate its impact given the current soft consumer environment.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41818982/will-microstrategys-42-billion-bitcoin-bet-boost-mstr-stock-further" target="_blank" rel="noreferrer noopener">Will MicroStrategy's $42 Billion Bitcoin Bet Boost MSTR Stock Further?</a>
Improved results are projected ahead to enable earlier deleveraging, with International Flavors having more attractive opportunities for cash use beyond just paying down debt, Tiano writes. Additionally, the company&#8217;s valuation is seen as attractive compared to historical levels and European peers.
Although the company maintained its full-year outlook, Tiano highlights an additional $30 million in incentive compensation due to better-than-expected performance, which increases next year's tailwind to $130 million.
This, along with other factors, has led the analyst to raise the 2025 EBITDA estimate to $2.265 billion, up from $2.161 billion previously. The 2026 EBITDA estimate is now projected at $2.277 billion, the analyst highlights.
Tiano raised the FY25 EPS estimate to $4.85 from $4.60, and FY26 estimate to $5.05 from $4.85.
Price Action: IFF shares are trading higher by 1.99% to $91.95&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41821244/blockfis-lending-license-revoked-by-california-regulator-over-violations" target="_blank" rel="noreferrer noopener">BlockFi's Lending License Revoked By California Regulator Over Violations</a></li>
</ul>

Equities

Upgrades

Markets

General

Fragrance Maker IFF Positioned For Growth With Revitalized R&D And Attractive Valuation: Analyst

Raymond James analyst Andy Marok maintains Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Outperform and raises the price target from $16 to $19.

GRND

Raymond James Maintains Outperform on Grindr, Raises Price Target to $19

Cannabis-focused consumer packaged goods company Auxly Cannabis Group Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/XLY#TSX">XLY</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTCQB">CBWTF</a>) released its financial results on Friday for the three and nine months ended Sept. 30, 2024.
&#8220;Our continued focus on efficient revenue growth and enhanced profitability has delivered another record-breaking quarter of financial results, highlighted by an 18% year-over-year increase in net revenue and record adjusted EBITDA of $8.3 million," said Hugo Alves, the company's CEO.
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$33.3 million ($24 million), compared to CA$28.2 million in the prior year's period, representing an increase of 18%.</li>
<li>Gross profit was CA$17.1 million, up from CA$4.6 million in the prior year's quarter.</li>
<li>Total expenses amounted to CA$14.1 million, down from CA$19.1 million in the same period of last fiscal year.</li>
<li>Net income amounted to CA$3.2 million, down from CA$31.6 million net income in the corresponding quarter of last year.</li>
<li>Adjusted EBITDA came in positive at CA$8.3 million, up from an adjusted EBITDA gain of CA$117 000 in the same quarter of last year.</li>
<li>Selling, general and administrative expenses were CA$8.5 million in the third quarter of 2024, CA$1.6 million or 16% lower than the same period in 2023.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40397950/auxly-cannabis-co-sets-q2-record-in-revenue-following-33-yoy-increase-reports-best-quarter-in-hi">Auxly Cannabis Co Sets Q2 Record In Revenue Following 33% YoY Increase, Reports Best Quarter In History</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Nine Months Ended Sept. 30, Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$87.7 million, compared to CA$74.2 million in the prior year's period, representing an increase of 18%.</li>
<li>Gross profit was CA$42.5 million, up from CA$18.5 million in the prior year's quarter.</li>
<li>Total expenses amounted to CA$46.6 million, down from CA$54.5 million in the same period of last fiscal year.</li>
<li>Net loss amounted to CA$20.8 million, compared to CA$9.5 million net income in the corresponding quarter of last year.</li>
<li>Adjusted EBITDA came in positive at CA$15.7 million, up from an adjusted EBITDA loss of $CA823 000 in the same quarter of last year.</li>
</ul>
<h3 class="wp-block-heading">Outlook</h3>
Going forward, Auxly will prioritize focused and efficient growth in its key product categories of vape, pre-roll and dried flower and continue to optimize and improve distribution and sales of its products.
<h3 class="wp-block-heading">CBWTF Price Action</h3>
Auxly's shares traded 4.57% higher at $0.0366 per share at the time of writing on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37924655/canadian-cannabis-companies-could-see-valuations-soar-by-up-to-300-with-tax-reform-">Canadian Cannabis Companies Could See Valuations Soar By Up To 300% With Tax Reform, New Report Shows</a></li>
</ul>

Cannabis

Earnings

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

TSX:XLY

Select Sector SPDR-Consumer Discretionary

Auxly Cannabis Co.: Q3 Net Revenue Climbs 18% YoY, Adjusted EBITDA Soars

Raymond James analyst Patrick Tyler Brown maintains GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Outperform and raises the price target from $47 to $50.

Raymond James Maintains Outperform on GFL Environmental, Raises Price Target to $50

Raymond James analyst Adam Tindle maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Outperform and raises the price target from $85 to $95.

FTNT

Raymond James Maintains Outperform on Fortinet, Raises Price Target to $95

Raymond James analyst John Davis maintains Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Strong Buy and raises the price target from $23 to $27.

FLYW

Raymond James Maintains Strong Buy on Flywire, Raises Price Target to $27

Dave Ramsey, the well-known personal finance guru, recently shared a timeless piece of advice from his grandmother that got people talking. He posted <a href="https://x.com/DaveRamsey/status/1847373355059761518">on X</a> and other social media, &#8220;There&#8217;s a great place to go when you&#8217;re broke: to work!&#8221; It was simple, blunt and to the point, just like Ramsey&#8217;s old-school philosophy on tackling financial troubles.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My Grandmother used to say, &quot;There&#39;s a great place to go when you&#39;re broke: to work!&quot;
&mdash; Dave Ramsey (@DaveRamsey) <a href="https://twitter.com/DaveRamsey/status/1847373355059761518?ref_src=twsrc%5Etfw">October 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year –<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing –<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<a href="https://www.benzinga.com/personal-finance/financial-advisors/24/01/36597689/millennials-are-the-most-likely-of-all-generations-to-experience-financial-ha">Financial hardships</a> seem all too common these days, so Ramsey&#8217;s message is a reminder that getting back on your feet often starts with good old-fashioned hard work. His grandmother&#8217;s advice isn't about waiting for the right time or finding a dream job, right? Wrong. It&#8217;s about getting your hands dirty, finding any job and using that money to get out of the hole. Action, not perfection, is the key.
This philosophy has struck a nerve with many of his followers and non-followers. Some fully agree, believing hard work is the first step toward financial independence. After all, the idea that nothing beats a steady paycheck is a <a href="https://www.benzinga.com/personal-finance/24/08/40512938/dave-ramseys-blunt-advice-your-finances-are-80-behavior-avoid-this-one-costly-mistake">core part of Ramsey&#8217;s teachings</a>. He's spent years encouraging people to get rid of debt, save and ultimately invest for the future and all of that starts with earning an income.
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
However, not everyone sees it the same way. The tweet has sparked debate about what it takes to find work in today&#8217;s economy. Many have pointed out that times have changed – finding a job isn't always as easy as just showing up. One user commented, &#8220;I have been unemployed from full-time work for almost two years; I currently work three part-time jobs. If only &#x2A;wanting&#x2A; to work and earn a livable wage was all it took.&#8221; Another added, &#8220;Show me a place that's not riddled with ghost jobs and scammers and I'll apply!&#8221; referring to the many job postings that seem more like dead ends than opportunities.
See Also: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
Despite the mixed reactions, the core of Ramsey&#8217;s message remains relatable for many, if not most people – when money is tight, any work is better than no work at all. And for many, that's the first step toward bigger opportunities.
After all, Ramsey recently <a href="https://www.benzinga.com/personal-finance/24/10/41146426/can-you-guess-the-top-5-careers-of-millionaires-according-to-dave-ramsey-spoiler-alert-theyre-no">brought attention to a study</a> that revealed the top five professions with the highest chance of producing billionaires and the findings may surprise you. The top careers are engineers ($91,010), accountants (CPA) ($77,250), teachers ($61,030), management ($107,360) and attorneys ($135,740).&nbsp;
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs – this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
</ul>

Startups

"There's A Great Place To Go When You're Broke: To Work," Says Dave Ramsey About A Piece Of Advice He Got

A nearly 3% Medicare payment cut for physicians is set to take effect in 2025, raising concerns about the potential impact on patient care, particularly in rural and underserved areas. The Centers for Medicare &amp; Medicaid Services (CMS) finalized the pay cut in early November, meaning physicians who provide <a href="https://www.benzinga.com/personal-finance/24/10/41570507/medicare-advantage-shake-up-how-health-insurance-plans-could-change-for-up-to-44-000-new-hampshi">Medicare-covered services</a> will see reduced reimbursement rates.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
<li>According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,<a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"> here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a></li>
</ul>
<h2 class="wp-block-heading">Medicare Payment Cuts</h2>
Under current rules, Medicare payments for physicians do not adjust with <a href="https://www.benzinga.com/personal-finance/24/11/41728751/even-as-inflation-cools-most-americans-cant-get-ahead-and-continue-living-paycheck-to-paycheck-r">inflation</a> as they do for hospitals, nursing homes and other health care facilities. This results in a fixed payment structure for physician services that is slowly eroded by rising operational costs.&nbsp;
As a result, many doctors feel financially squeezed, especially as their operating costs are expected to increase by an estimated 3.5% in 2025, according to CMS. The American Medical Association (AMA) has emphasized that these cuts significantly strain practices, particularly smaller ones or those in rural areas.
For the past five years, Congress has delayed or partially offset Medicare pay cuts through temporary measures, often in the final days of the legislative calendar. In 2024, lawmakers are once again discussing options to avert the cut. One bipartisan proposal, the Bipartisan Medicare Patient Access and Practice Stabilization Act, aims to stop the planned reduction and provide physicians a partial 1.8% inflationary boost.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
<h2 class="wp-block-heading">The Implications for Medicare Patients</h2>
Physician advocates worry that reducing Medicare reimbursements could limit <a href="https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy">patients' access to care</a>.&nbsp;
"For physician practices operating on small margins already, this means it is harder to acquire new equipment, harder to retain staff, harder to take on new Medicare patients and harder to keep the doors open, particularly in rural and underserved areas," says Dr. Bruce A. Scott, President of the American Medical Association.
Dr. Scott also stated that Medicare's plan to pay physicians less while doctors' costs continue to increase is an unsustainable trend.&nbsp;
A primary concern is that providers in rural or underserved areas may feel compelled to close practices, retire earlier or reduce the number of Medicare patients they accept. Operating with lower Medicare reimbursement rates often means tighter margins for these practices.&nbsp;
As Dr. Scott noted, the financial stress can be severe enough to drive some physicians out of independent practice, pushing them to seek employment in larger health care systems or retire early.
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">What's Next?</h2>
Congress is expected to consider the Bipartisan Medicare Patient Access and Practice Stabilization Act and similar proposals before the end of the year. The AMA and the American College of Surgeons (ACS) hope this will lead to a longer-term solution that provides predictable and fair Medicare reimbursement rates. A bipartisan group of over 200 members of Congress supported a letter to the House of Representatives calling for a legislative solution to prevent future Medicare pay cuts.
What happens with the upcoming cut and whether Congress can pass a bill to avert it remains to be seen. However, each year of temporary fixes increases the pressure to develop a more sustainable solution for <a href="https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs">Medicare reimbursements</a>. Many are watching to see if this year will bring new actions to prevent annual cuts and ensure that Medicare patients continue to get the care they need from their providers.&nbsp;
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

Doctors' 3% Medicare Pay Cut – Could It Lead to Fewer Providers Accepting Medicare Patients?

ASML

ASML Spokesperson Says Co Was Hit By An Outage On Friday; Claims IT Issue Is Resolved And All Systems Recovered

WIIM

CBUS

Cibus shares are trading higher after the company reported better-than-expected Q3 sales result.

Article via <a href="https://elplanteo.com/mercado-de-cannabis-en-puerto-rico-entrevista-prich/">El Planteo</a>
"Puerto Rico is a paradise for a cannabis entrepreneur," says Jaime Rengifo, CEO of <a href="https://elplanteo.com/prich/">Prich Biotech</a>, often regarded as the largest <a href="https://www.benzinga.com/money/best-latin-american-cannabis-companies">cannabis company in Latin America</a>. Since his arrival on the island, Rengifo has closely observed how this relatively small region has become a Latin American leader in <a href="https://elplanteo.com/cannabis-medicinal/">medicinal cannabis</a>, with a local market now surpassing $250 million annually. For Rengifo, however, success isn't just about numbers, it's about the model, education and accessibility that have fostered sustained growth and elevated product quality.
Watch the full episode of <a href="https://www.youtube.com/live/TzYjAsaQiFc?si=Tk6kE5Vi-nmyw980">&#8220;El Planteo Live&#8221;</a> on <a href="https://www.youtube.com/live/TzYjAsaQiFc?si=Tk6kE5Vi-nmyw980">YouTube</a>.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="El DIAMANTE EN BRUTO del CANNABIS LATINO: el SECRETO de PUERTO RICO" width="500" height="281" src="https://www.youtube.com/embed/TzYjAsaQiFc?start=1200&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Rengifo attributes Puerto Rico's progress in <a href="https://www.benzinga.com/cannabis">medicinal cannabis</a> to a functional regulatory system that allows patients to acquire medical marijuana from dispensaries located throughout the island. "People have access, patients can access products, in various formulations, various formats," he explains, referring to the range of consumption options available in Puerto Rico, which includes capsules, concentrates, <a href="https://elplanteo.com/comestibles-de-marihuana-guia-para-su-consumo/">edibles</a>, oils and even transdermal patches. While smoking cannabis is prohibited, the law allows for <a href="https://www.benzinga.com/topic/vaping">vaping</a>, an adjustment he believes has attracted a broader, more responsible consumer base.
See also: <a href="https://www.benzinga.com/markets/cannabis/23/09/33840003/latin-americas-best-kept-cannabis-secret-meet-the-biggest-marijuana-company-in-the-region">Latin America&#8217;s Best-Kept Cannabis Secret: Meet The Biggest Marijuana Company In The Region</a>
<h2 class="wp-block-heading">Education And Accessibility: Puerto Rico's Formula For Effective Medicinal Cannabis</h2>
For Rengifo, Puerto Rico's real triumph isn't just having an industry that works, but in how it works. He says the key lies in education and ensuring that access to medicinal cannabis is a right, not a privilege.
As CEO of Prich Biotech, Rengifo has championed educational programs to help both patients and doctors understand the benefits and correct use of the plant. "I don't see a reason why we should charge for a license [medical marijuana card] to obtain cannabis products," he says, adding that the system should ease access to treatments rather than complicate it with fees or unnecessary restrictions. "I believe cannabis is a therapeutic product."
Looking toward 2025, Rengifo and his team at Prich Biotech aim to further expand the reach of medicinal cannabis in Puerto Rico, particularly among senior citizens and military veterans &#8211; two groups he says could greatly benefit from the market. Just last week, Prich Biotech hosted an event targeting the baby boomer community. He said a surprising number of seniors not only showed interest in cannabis but were already familiar with its benefits.
"I really thought seniors would have a cultural barrier against cannabis," he admits. Yet the response was so positive that Prich Biotech is already planning a large-scale educational campaign for 2025 to reach more patients and reduce the stigma around medicinal cannabis use.
<h2 class="wp-block-heading">Challenges And Opportunities In A Responsibly Growing Cannabis Market </h2>
Rengifo recognizes that maintaining a competitive industry requires not only investment but ongoing adaptation. In Puerto Rico, he notes, cannabis initially had high prices, due partly to the early costly business models. However, as the market has matured, prices have dropped and the range of offerings has diversified. For him, this is crucial to popularize medicinal cannabis. "I can't keep prices high if I want to expand the industry and transform it," he explains.
Part of Rengifo&#8217;s strategy has been to optimize all cultivation and production processes at Prich Biotech. "We've automated production, standardized our cultivation processes," he says. Today, Prich Biotech can produce more grams of cannabis per square foot, maintaining consistent quality levels of <a href="https://elplanteo.com/que-es-el-thc/">THC</a> and <a href="https://elplanteo.com/que-es-el-cbd/">CBD</a>, making them, as he puts it, "very competitive in the market."
<h2 class="wp-block-heading">Puerto Rico's Potential: Preparing For A Cannabis Export Scenario</h2>
Rengifo envisions Puerto Rico not only as a regional model but as a potential benchmark for the global medicinal cannabis industry. The island, located about 1,000 miles southeast of Miami, Florida, boasts a historical pharmaceutical presence and robust infrastructure, which he believes could underpin the cannabis industry if U.S. laws move toward rescheduling or descheduling the plant at the federal level.
"We are preparing for the future," he says, noting that Prich Biotech is investing in Good Manufacturing Practices (GMP) certifications and standards that could allow it to export to markets like Europe and the United States.
"Puerto Rico is an island where all major pharmaceutical companies have a production facility… and cannabis, too, will become a valuable resource for Puerto Rico," Rengifo emphasizes. With a regulatory framework that models pharmaceutical quality standards, Puerto Rico, a US territory, could emerge as a leader in exporting medicinal cannabis—a goal Rengifo and his team are set on achieving.
Rengifo's vision, combined with Prich Biotech's focus on accessibility, education and efficiency paints a promising picture for Puerto Rico's medicinal cannabis industry. "This is a diamond in the rough," he says, and the journey is just beginning.
Cover image made with AI.

Latin America

Interview

'Diamond In The Rough' Of Latin American Cannabis: Puerto Rico's Success Secret Explained

Raymond James analyst Brian Vaccaro maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Strong Buy and raises the price target from $22 to $25.

FWRG

Raymond James Maintains Strong Buy on First Watch Restaurant Gr, Raises Price Target to $25

Citigroup analyst Fatima Boolani maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $150 to $157.

DDOG

Citigroup Maintains Buy on Datadog, Raises Price Target to $157

NUTX

Nutex Health shares are trading higher after the company reported better-than-expected Q3 sales results.

TOST

Watching Toast; Shares See Volume To The Upside Amid Comments Live On CNBC From Josh Brown

Agilon Health (AGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 27. Analyst Michael Ha from ...

Maintaining Equilibrium: Hold Rating on Agilon Health Amidst Growth and Risk

agilon health sees double downgrade at BoA on 'deteriorating' MA environment

Wolfe's tax loss selling stocks within communications, discretionary, staples, energy, financials, health care

Warning: AGL is at high risk of performing badly

Citi downgraded Agilon Health (AGL) to Sell from Neutral with a price target of $2.50, down from $7, ahead of the Q3 earnings report. The company's...

Agilon Health downgraded to Sell from Neutral at Citi

agilon cut to sell at Citi on Medicare headwinds

agilon health GAAP EPS of -$0.29 misses by $0.18, revenue of $1.45B misses by $20M

William Blair downgraded Agilon Health (AGL) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-time, mark...

Agilon Health downgraded to Market Perform from Outperform at William Blair

Deutsche Bank analyst George Hill lowered the firm's price target on Agilon Health (AGL) to $2 from $4 and keeps a Hold rating on the shares post t...

Agilon Health price target lowered to $2 from $4 at Deutsche Bank

agilon cut to market perform by William Blair on Q3 earnings report

ACHC

APLS

APTV

BBWI

BIIB

BMRN

CELH

CHTR

DLTR

DXCM

ETSY

FIVE

FOXF

IONS

IRDM

LCID

LULU

MBLY

MRNA

NVST

NYCB

PARA

PRGO

PTEN

QDEL

RGEN

RIVN

SIRI

SNAP

ULTA

XRAY

Legal

Press Releases

AGILON ALERT: Bragar Eagel & Squire, P.C. is Investigating Agilon Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Agilon Health, Inc, B. Riley Financial, Charles River Laboratories, and Getty Images Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

agilon health to Participate at 2024 Wells Fargo Healthcare Conference

AGILON HEALTH INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of agilon health, inc. - AGL

AGILON HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of agilon health, inc. - AGL

agilon health Sets Date to Report Third Quarter 2024 Financial Results

agilon health to Participate at 2024 Wolfe Research Healthcare Conference

agilon health Reports Third Quarter 2024 Results

GETY

RILY

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Holdings

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Option Care Health

Premier

Pennant Gr

Privia Health Gr

R1 RCM

RadNet

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Hldgs

Citigroup

Evercore ISI Group

B of A Securities

Deutsche Bank

Benchmark

Agilon Health shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform.

Comments

Agilon Health

Agilon Health (AGL) オプション

Agilon Health (NYSE:AGL) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル